Well before launching the horrifying campaign against Ukraine a year ago, Vladimir Putin had been undermining Russia as well: normalizing corruption on a massive scale, and suppressing dissent and democracy. One of the darkest moments on that trajectory was the poisoning of the opposition leader Alexey Navalny with the nerve agent novichok. Navalny and a team of investigators had illustrated the corruption of Putin and his circle in startling detail, and Navalny began travelling the country to launch a bid for the Presidency. “Every time when I heard Navalny giving an interview, I don’t think there was one interview where he wasn’t asked, ‘How come you’re still alive? How come they still haven’t they killed you?,’ ” recalls the Russian activist Maria Pevchikh, the head of investigations and media for Navalny’s Anti-Corruption Foundation. “And Navalny is rolling his eyes saying, ‘I don’t know, I’m tired of this question, stop asking. I don’t know why I’m still alive and why they haven’t tried to assassinate me.’ ” Pevchikh was travelling with Navalny when he was poisoned, and helped uncover the involvement of the F.S.B. security services. After surviving the assassination and recuperating abroad, Navalny returned to Russia only to be arrested and then detained in a penal colony. “I think Putin wants him to suffer a lot and then die in prison,” Pevchikh tells David Remnick. Still, she maintains hope. “The situation is so chaotic, specifically because of the war,” she says. “Is the likelihood of Navalny being released when the war ends high? I think it is almost certain.” Pevchikh also served as an executive producer of the documentary “Navalny,” which is nominated for an Academy Award.

New Yorker Radio Hour listeners, we want to hear from you. We have a few questions about the show and how you listen to it. The survey takes about twenty minutes, and your feedback will help us make our podcast better. Take the survey here.

Johnson & Johnson Drops, Kraft Heinz Declines, Nathan's Famous Surges

Stock Movers

J&J earnings, 2026 guidance, and drug sales

The AI-powered Podcast Player